JP2007538008A5 - - Google Patents

Download PDF

Info

Publication number
JP2007538008A5
JP2007538008A5 JP2007510880A JP2007510880A JP2007538008A5 JP 2007538008 A5 JP2007538008 A5 JP 2007538008A5 JP 2007510880 A JP2007510880 A JP 2007510880A JP 2007510880 A JP2007510880 A JP 2007510880A JP 2007538008 A5 JP2007538008 A5 JP 2007538008A5
Authority
JP
Japan
Prior art keywords
matrix
methadone
formulation
styrene
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007510880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007538008A (ja
JP5250257B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/014240 external-priority patent/WO2005110381A1/en
Publication of JP2007538008A publication Critical patent/JP2007538008A/ja
Publication of JP2007538008A5 publication Critical patent/JP2007538008A5/ja
Application granted granted Critical
Publication of JP5250257B2 publication Critical patent/JP5250257B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007510880A 2004-04-29 2005-04-26 メサドン局所組成物およびその使用方法 Expired - Fee Related JP5250257B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56668604P 2004-04-29 2004-04-29
US60/566,686 2004-04-29
PCT/US2005/014240 WO2005110381A1 (en) 2004-04-29 2005-04-26 Topical methadone compositions and methods for using the same

Publications (3)

Publication Number Publication Date
JP2007538008A JP2007538008A (ja) 2007-12-27
JP2007538008A5 true JP2007538008A5 (https=) 2008-04-17
JP5250257B2 JP5250257B2 (ja) 2013-07-31

Family

ID=35393974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007510880A Expired - Fee Related JP5250257B2 (ja) 2004-04-29 2005-04-26 メサドン局所組成物およびその使用方法

Country Status (21)

Country Link
US (1) US20050244486A1 (https=)
EP (1) EP1740162A4 (https=)
JP (1) JP5250257B2 (https=)
KR (1) KR20070007850A (https=)
CN (1) CN1976689A (https=)
AR (1) AR048878A1 (https=)
AU (2) AU2005244214B2 (https=)
BR (1) BRPI0510428A (https=)
CA (1) CA2563489C (https=)
CR (1) CR8722A (https=)
EA (1) EA011423B1 (https=)
IL (1) IL178661A0 (https=)
ME (1) MEP25008A (https=)
MX (1) MXPA06012563A (https=)
NO (1) NO20065455L (https=)
NZ (1) NZ550963A (https=)
RS (1) RS20060605A (https=)
TW (1) TW200605870A (https=)
UA (1) UA88464C2 (https=)
WO (1) WO2005110381A1 (https=)
ZA (1) ZA200608923B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1774964B1 (en) * 2005-10-13 2014-08-06 Nitto Denko Corporation Nicotine transdermal preparation and production method thereof
WO2008051527A2 (en) * 2006-10-23 2008-05-02 Psivida, Inc. Sustained release of agents for localized pain management
JP5704801B2 (ja) * 2008-08-21 2015-04-22 ニプロパッチ株式会社 粘着性組成物及び経皮吸収型製剤
GB2481619B (en) * 2010-06-30 2012-06-20 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168000A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの3つの成分の塩
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
WO2016088132A1 (en) 2014-12-01 2016-06-09 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
WO2022155179A2 (en) * 2021-01-14 2022-07-21 The Trustees Of Indiana University Methods to predict effects of perioperative administration of methadone to optimize pain relief and avoid adverse effects

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
EP0399432B1 (en) * 1989-05-25 1994-06-22 Takeda Chemical Industries, Ltd. Transdermal therapeutic composition
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
AU5551394A (en) * 1992-11-09 1994-06-08 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5883115A (en) * 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
US5589480A (en) * 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
EP1021204B1 (en) * 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
GB9804885D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
DE19850517B4 (de) * 1998-11-03 2004-02-12 Lts Lohmann Therapie-Systeme Ag Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
GB9828480D0 (en) * 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP2003523405A (ja) * 2000-02-22 2003-08-05 セレジー カナダ インコーポレイテッド 睡眠改善のための方法および組成物
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DE60220703T2 (de) * 2001-10-22 2008-02-07 3M Innovative Properties Co., St. Paul Verpackung für transdermale/transmucosale pflaster
US6713470B2 (en) * 2002-01-22 2004-03-30 Ml Laboratories Plc Method of treatment

Similar Documents

Publication Publication Date Title
JP2007538008A5 (https=)
ATE383849T1 (de) Transdermale pharmazeutische zusammensetzung
WO2004078122A3 (en) Invisible patch for active agnet controlled delivery
JP2019537460A (ja) 有益物の局所送達のためのキット及び方法
WO2007066149A3 (en) Topical pharmaceutical compositions
PT957900E (pt) Composicoes e metodos para aplicacao topica de agentes terapeuticos
TW201043270A (en) Methods of administration of a dermatological agent to a subject
WO2011029948A3 (de) Transdermales therapeutisches system zur verabreichung von fentanyl oder einem analogstoff davon
CN107771071A (zh) 用于向皮肤提供有益效果的多层局部施用的制品
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
JP2005508963A5 (https=)
US20050181028A1 (en) Topical composition and method for treating occlusive wounds
RU2007101538A (ru) Применение фармацевтической композиции, содержащей кальцитриол и пропионат клобетазола, для лечения псориаза
US12419829B2 (en) Topical product hands-free applicator drug delivery system and methods of making and using the same
ES2391409T3 (es) Composición antifúngica
JP2009522207A5 (https=)
WO2006088945A3 (en) Granulysin peptides and methods of use thereof
CN102988277A (zh) 一种治疗皮肤疣、甲真菌病和胼胝等皮肤病的油膏
CA2519789A1 (en) Aplidine for multiple myeloma treatment
US8367683B2 (en) Composition and method for treatment of warts
JPH01230514A (ja) エアゾール型外用貼付剤
JP3207257B2 (ja) 貼付剤
JPH05245172A (ja) 長時間密封治療システム
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
EP1758922B8 (en) Peptide substance restoring function of respiratory organs